ArticleBMC cardiovascular disorders2026
Association of cholesterol, high-density lipoprotein, and glucose index and modified indices in predicting cardiovascular diseases incidence among population with cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide prospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCardiovascular-kidney-metabolic (CKM) syndrome, characterized by the interplay of metabolic risk factors, chronic kidney disease, and cardiovascular dysfunction, is a key driver of cardiovascular disease (CVD) incidence. The cholesterol, high-density lipoprotein, and glucose (CHG) index, which integrates total cholesterol, high-density lipoprotein, and fasting blood glucose, and its modified indices (combined with obesity indicators) have potential for CVD risk prediction. However, their role across CKM stages 0-3 remains unclear.
methodsA nationwide prospective cohort study included 5,404 participants with CKM stages 0-3, screened from 17,708 individuals screened between 2011 and 2020. CHG index and modified indices (CHG-BMI, CHG-Wc, CHG-WHtR) were calculated. Logistic regression, restricted cubic spline (RCS) analysis, subgroup analysis, and sensitivity analysis were used to evaluate associations with CVD incidence and identify exploratory threshold association.
resultsDuring follow-up, 25.5% of participants developed CVD. CHG and modified indices were independently associated with increased CVD risk (all P < 0.001). In fully adjusted models, CHG as continuous data showed a 28% higher risk (OR = 1.28, 95% CI: 1.06-1.58) of outcome, and CHG-WHtR was 54% higher (OR = 1.28, 95% CI: 1.16-2.04). Meanwhile, the highest quartile (Q4) of CHG-WHtR was associated with a 43% higher risk (OR = 1.43, 95% CI: 1.03-1.98) compared to Q1, while CHG-BMI (OR = 1.68, 95% CI: 1.22-2.31) showed stronger associations. RCS analysis identified exploratory inflection points like CHG ≥ 5.15 and CHG-WHtR ≥ 2.41, above which CVD risk significantly increased (P < 0.005) and validated by bootstrap sampling. Subgroup analysis confirmed consistent associations across age, gender, and CKM stages subpopulations. Multiple sensitivity analysis supported the robustness of these associations across CKM stages.
conclusionCHG index and its modified indices, particularly CHG-WHtR and CHG-Wc, are valuable indicators associated with reported incident CVD across CKM stages 0-3. Their stage-specific associations and exploratory threshold association support their utility in risk stratification for CKM syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.